Inactive Instrument

Laboratorio Reig Jofre SA Share Price BME

Equities

ES0165359011

Pharmaceuticals

End-of-day quote BME
- EUR - Intraday chart for Laboratorio Reig Jofre SA

Financials

Sales 2024 * 35Cr 38Cr 3.16TCr Sales 2025 * 38Cr 41Cr 3.43TCr Capitalization 23Cr 25Cr 2.09TCr
Net income 2024 * 1.1Cr 1.19Cr 100Cr Net income 2025 * 1.4Cr 1.52Cr 126.72Cr EV / Sales 2024 * 0.78 x
Net Debt 2024 * 3.95Cr 4.28Cr 357.52Cr Net Debt 2025 * 3.33Cr 3.61Cr 301.4Cr EV / Sales 2025 * 0.7 x
P/E ratio 2024 *
20.9 x
P/E ratio 2025 *
16.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 21.21%
More Fundamentals * Assessed data
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Transcript : Laboratorio Reig Jofre, S.A., 2023 Earnings Call, Mar 13, 2024
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Spain’s Reig Jofre Names New CFO MT
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Transcript : Laboratorio Reig Jofre, S.A., Q4 2022 Earnings Call, Mar 07, 2023
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Why Europe's drug shortages may get worse RE
Reig Jofre JV Inks Deal with Indian Pharmaceutical to Commercialize Biosimilar Medicine MT
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Laboratorio Reig Jofre, S.A.(BME:RJF) dropped from S&P Global BMI Index CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Laboratorio Reig Jofre, S.A.’s Equity Buyback announced on July 18, 2019 has Expired. The company has repurchased 74,107 shares, representing 0.1% for €0.26 million. CI
Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news
Managers TitleAgeSince
Chief Executive Officer 56 01/06/01
Chief Tech/Sci/R&D Officer - 01/03/01
Chief Operating Officer 52 01/03/01
Members of the board TitleAgeSince
Chief Executive Officer 56 01/06/01
Director/Board Member - 31/14/31
Director/Board Member - 31/14/31
More insiders
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
Calendar
More about the company